Get the Stockscreener App
6.45
3.50%
0.218
Dermata Therapeutics Inc stock is traded at $6.45, with a volume of 96,981.
It is up +3.50% in the last 24 hours and up +0.69% over the past month.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.
See More
Previous Close:
$6.232
Open:
$6.135
24h Volume:
96,981
Relative Volume:
6.80
Market Cap:
$41.14M
Revenue:
-
Net Income/Loss:
$-11.27M
P/E Ratio:
-0.3012
EPS:
-21.4132
Net Cash Flow:
$-9.40M
1W Performance:
-7.75%
1M Performance:
+0.69%
6M Performance:
-47.56%
1Y Performance:
-73.99%
1-Day Range:
$6.01
$6.88
1-Week Range:
$5.941
$7.33
52-Week Range:
$5.739
$37.90
Dermata Therapeutics Inc Stock (DRMA) Company Profile
Name
Dermata Therapeutics Inc
Sector
Industry
Phone
(858)-223-0882
Address
3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO
Compare DRMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DRMA
Dermata Therapeutics Inc
|
6.45 | 3.97M | 0 | -11.27M | -9.40M | -21.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Dermata Therapeutics Inc Stock (DRMA) Latest News
Why Dermata Therapeutics Inc. Equity Warrant stock attracts strong analyst attentionLong Term Stock Planner with Safety Checks - Newser
Can a trend reversal in Dermata Therapeutics Inc. Equity Warrant lead to recoveryHigh Return Strategy with Low Risk - Newser
Will Dermata Therapeutics Inc. bounce back from current supportFree Weekly Growth Stock Entry Point Alerts - Newser
Analyzing recovery setups for Dermata Therapeutics Inc. investorsTrend Confirmation Scanner with Entry Focus - Newser
How to track smart money flows in Dermata Therapeutics Inc.Free High Return Stock Focus With Safety - Newser
What catalysts could drive Dermata Therapeutics Inc. Equity Warrant stock higher in 2025Wealth Building Opportunities For Beginners - jammulinksnews.com
Dermata Therapeutics Inc. Equity Warrant stock volume spike explainedFree ROI Driven Equity Selection With Safety - Newser
How to escape a deep drawdown in Dermata Therapeutics Inc. Equity WarrantLong Term Stock Planner with Safety Checks - Newser
Using data models to predict Dermata Therapeutics Inc. stock movementStock Performance Summary Over One Year - Newser
Volume spikes in Dermata Therapeutics Inc. Equity Warrant stock – what they meanLow Risk High Confidence Watchlist Builder - Newser
Will Dermata Therapeutics Inc. stock benefit from AI tech trendsCommunity Picked Stocks with Trade Insights - Newser
How to read the order book for Dermata Therapeutics Inc. Equity WarrantFree Reliable Alerts for Daily Stock Movers - Newser
Is Dermata Therapeutics Inc. showing signs of accumulationFree Smart Trade Plans With Risk Protection - Newser
How volatile is Dermata Therapeutics Inc. Equity Warrant stock compared to the marketChart Pattern Insights Backed By Experts - jammulinksnews.com
Why is Dermata Therapeutics Inc. stock attracting strong analyst attentionTop Growth Opportunities For Fast Growth - jammulinksnews.com
What makes Dermata Therapeutics Inc. stock price move sharplyWatchlist Generator With Real-Time Entry - Newser
Will Dermata Therapeutics Inc. Equity Warrant continue its uptrendQuick Profit Setup with Signal Forecast - Newser
How to forecast Dermata Therapeutics Inc. Equity Warrant trends using time series - Newser
Dermata Therapeutics Inc. Company Revenue and Profit Trends: A Deep DiveStable Profit Zone and Loss Control Analysis - Newser
What data driven models say about Dermata Therapeutics Inc. Equity Warrant’s futureSummary of Trade Cycles in 5-Year Range - Newser
Why Dermata Therapeutics Inc. Equity Warrant stock is on top investor watchlistsFree Investment Strategy With Low Risk - Newser
Will Dermata Therapeutics Inc. stock go up soonAI Enhanced Strategy for Portfolio Growth - Newser
Is Dermata Therapeutics Inc. a growth stock or a value stockRetirement Planning Review With Proven Results - jammulinksnews.com
What are Dermata Therapeutics Inc. company’s key revenue driversAI Powered Growth Plan For 2025 - jammulinksnews.com
How strong is Dermata Therapeutics Inc. Equity Warrant company’s balance sheetExpert Picks Entry Points For 2025 - jammulinksnews.com
What’s next for Dermata Therapeutics Inc. Equity Warrant stock priceWeekly Market Direction and Sector Summary - Newser
When is the best time to buy Dermata Therapeutics Inc. stockFree Weekly Hot Picks With Buy Confidence - Newser
Dermata Therapeutics Inc. Equity Warrant stock trendline breakdownAI Pattern Recognition and Trade Prediction - Newser
What are analysts’ price targets for Dermata Therapeutics Inc. in the next 12 monthsEntry Signal Updates For Fast Growth - jammulinksnews.com
Dermata Therapeutics Inc. Equity Warrant Earnings Report Breakdown: What Investors Should KnowDay Trading Setup and Momentum Analysis - Newser
Dermata Therapeutics to implement 1-for-10 reverse stock split on August 1 - Investing.com Nigeria
Dermata Therapeutics Announces Reverse Stock Split - TipRanks
What recovery options are there for Dermata Therapeutics Inc.Buy List With Technical Entry Triggers - Newser
Will Dermata Therapeutics Inc. continue its uptrendMarket Momentum and Signal Alerts Suggest Reversal - metal.it
Dermata Therapeutics (NASDAQ:DRMA) Shares Up 0.5% – Should You Buy? - Defense World
MyMD Pharmaceuticals (NASDAQ:MYMD) Shares Down 11.5% – Here’s Why - Defense World
Published on: 2025-07-30 01:31:25 - Newser
Published on: 2025-07-30 01:14:29 - Newser
Dermata Therapeutics Inc Stock (DRMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):